Financial Publications

In this publications section you can find the Company’s Annual Reports, Quarterly Reports/Statements, our Sustainability Report as well as non-financial statements. Furthermore, there are available presentations held at Investor Relations events and analyst calls.

SEC Filings

On this page you can also find all documents published in realation to our public listing on NASDAQ. 

For the original documents published on the EDGAR ("Electronic Data Gathering, Analysis, and Retrieval") database of the U.S. Securities and exchange commission ("SEC"), please use the below link.

Link to SEC EDGAR platform

Three shareholders, Novo Holdings A/S, T. Rowe Price Group Inc. and Mubadala Investment Company, currently hold more than 5% of the shares of Evotec SE. The free float according to the definition of the Frankfurt Stock Exchange is approx. 72% according to our estimates (Evotec: 09/2023).

Financial & Sustainability Reports

Please find below Evotec's financial reports and sustainability reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. 

An overview of all published sustainability-related reports can also be found in the ESG Performance section.

2024

2023

2022

Annual Report


Sustainability Report


Financial Statements


Preliminary FY 2022 Results


Interim Statement 9M 2022


Half-year Report 2022


Interim Statement Q1 2022

2021

Annual Report 


Sustainability Report


Financial Statements


Interim Statement 9M


Half-year Report


Interim Statement Q1

2020

Annual Report


Sustainability Report


Financial Statements


Quarterly Statement 9M


Half-year Report


Quarterly Statement Q1

2019

Annual Report


Financial Statements


Separate Non-financial Group Report 


Quarterly Statement 9M


Half-year Report 


Webcast / Conference Call Regarding the Acquisition of Just.Bio


Quarterly Statement Q1

2018

Annual Report


Financial Statements 


Separate Non-financial Group Report


Webcast / Conference Call Regarding the Fiscal Year 2018 Results


Quarterly Statement 9M


Half-year Report 


Quarterly Statement Q1

2017

Annual Report


Financial Statements


Separate Non-financial Group Report


Webcast / Conference Call Regarding the Fiscal Year 2017 Results


Quarterly Statement 9M


Half-year Report


Conference Call / Webcast Regarding the Acquisition of Aptuit


Quarterly Statement Q1

2016

Annual Report 


Financial Statements


Conference Call / Webcast Regarding Strategic Collaboration with Celgene


Quarterly Statement Q3


Conference Call / Webcast Regarding the Offer to Acquire Cyprotex


Half-year Report


Quarterly Statement Q1

2015

2014

Annual Report


Financial Statements


Conference Call / Webcast Announcing Negotiations on Major Collaboration with Sanofi


Nine-month Interim Report


Half-year Report


First Quarter Report

2013

2012

2011

Annual Report


Financial Statements


Third Quarter Report


Conference Call / Webcast Announcing License Agreement with Roche


Half Year Report


Conference Call and Webcast Announcing the Acquisition of Compound Focus, Inc.


First Quarter Report


Conference Call and Webcast Announcing the Acquisition of Kinaxo

2010

Annual Report


Financial Statements


Conference Call and Webcast Announcing the Alliance With MedImmune


Third Quarter Report 


Half Year Report


Conference Call and Webcast Announcing the Acquisition of DeveloGen


First Quarter Report

2009

Annual Report


Financial Statements


Third Quarter Report


Half Year Report


First Quarter Report

2008

Annual Report


Financial Statements


Third Quarter Report


Half Year Report


First Quarter Report

2007

Annual Report


Financial Statements


Third Quarter Report


Half Year Report


First Quarter Report

2006

Annual Report


Financial Statements According to HGB


Third Quarter Report


Second Quarter Report


First Quarter Report

2005

Annual Report


Third Quarter Report


Second Quarter Report


First Quarter Report


New Segmental P&L Statements

2004

Annual Report


Third Quarter Report 


Second Quarter Report


First Quarter Report

2003

Annual Report


Third Quarter Report


Second Quarter Report


First Quarter Report

2002

Annual Report


Third Quarter Report


Second Quarter Report


First Quarter Report 

2001

Annual Report


Third Quarter Report 


Second Quarter Report


First Quarter Report 

2000

Annual Report


Third Quarter Report


Second Quarter Report 


First Quarter Report 


Oxford Asymmetry International plc 2000 Interim Statement

1999

Annual Report


Third Quarter Report


Oxford Asymmetry International plc Annual Report 1999

IR & ESG Presentations

Presentations 2024

Presentations 2023

Former Presentations

Logo Evotec white
Evotec has the right technologies & disease understanding to meet our partners' evolving needs: a comprehensive disease knowledge at the molecular level, cutting-edge technologies & platforms to translate this expertise into effective precision medicines.